Table 3.
Clinical trials with bevacizumab in first-line treatment.
| Study | No. of patients | Design | Treatment | Primary end point | Results | p |
|---|---|---|---|---|---|---|
| Kabbinavar et al. [62] | 104 | Phase 2, randomized | FU/LV versus | TTP | 5.2 versus 7.4 months | 0.013 |
| Low dose bevacizumab + FU/LV High dose bevacizumab + FU/LV |
Best response rate | 17% versus 32% | 0.086 | |||
|
| ||||||
| Kabbinavar et al. [63] | 209 | Phase 2, randomized | FU/LV + placebo versus FU/LV + bevacizumab | OS | 12.9 versus 16.6 months; HR, 0.79 | 0.16 |
|
| ||||||
| Hurwitz et al. [64] | 813 | Phase 3, double-blind, RCT | IFL + placebo versus IFL + bevacizumab | OS | 15.6 versus 20.3 months; HR, 0.66 | <0.001 |
|
| ||||||
| NO 16966 [65] | 1401 | Phase 3, double-blind, RCT | CapeOx + placebo or CapOx + bevacizumab versus FOLFOX + placebo or FOLFOX + bevacizumab | PFS | HR, 0.83; 95% CI, 0.72–0.95 | 0.0023 |
|
| ||||||
| Passardi et al. [69] | 376 | Phase 3, randomized | FOLFIRI or FOLFOX + bevacizumab versus FOLFIRI or FOLFOX | PFS | HR, 0.86; 95% CI, 0.70–1.07 | 0.182 |
No.: number; TTP: time to progression; RCT: randomized controlled trial; OS: overall survival; HR: hazard ratio; PFS: progression-free survival; CI: confidence interval.